Table 2 Associations between the LANR and other clinicopathologic characteristics in the training and validation cohorts.

From: Nomograms based on the lymphocyte–albumin–neutrophil ratio (LANR) for predicting the prognosis of nasopharyngeal carcinoma patients after definitive radiotherapy

Characteristics

Training set

Validation set

LANR

Total

Chi-square

P

LANR

Total

Chi-square

P

LOW

High

LOW

High

Age

0.358

0.6145

   

1.142

0.3602

  ≥ 60

29 (33.7%)

57 (66.3%)

86

  

45 (26.0%)

128 (74.0%)

173

  

  < 60

158 (30.5%)

360 (69.5%)

518

  

10 (35.7%)

18 (64.3%)

28

  

Gender

0.330

0.6255

   

2.614

0.1501

 Male

137 (31.6%)

296 (68.4%)

433

  

45 (30.4%)

103 (69.3%)

148

  

 Female

50 (29.2%)

121 (70.8%)

171

  

10 (18.9%)

43 (81.1%)

53

  

T stage

2.387

0.1342

   

4.914

0.0279

 1–2

90 (28.2%)

229 (71.8%)

319

  

19 (20.0%)

76 (80.0%)

95

  

 3–4

97 (34.0%)

188 (66.0%)

285

  

36 (34.0%)

70 (66.0%)

106

  

N stage

0.053

0.839

   

0.283

0.5784

 0–1

45 (30.2%)

104 (69.8%)

149

  

14 (30.4%)

32 (69.6%)

46

  

 2–3

142 (31.2%)

313 (68.8%)

455

  

41 (26.5%)

114 (73.5%)

155

  

TNM stage

1.193

0.3123

   

1.228

0.3555

 I–II

22 (25.9%)

63 (74.1%)

85

  

5 (18.5%)

22 (81.5%)

27

  

 III–IV

165 (31.8%)

354 (68.2%)

519

  

50 (28.7%)

124 (71.3%)

174

  

ECOG performance scale

2.029

0.1806

   

1.881

0.1933

 0

101 (28.7%)

251 (71.3%)

352

  

30 (24.0%)

95 (76.0%)

125

  

 1–2

86 (34.1%)

166 (65.9%)

252

  

25 (32.9%)

51 (67.1%)

76

  

Treatment

1.979

0.1858

   

0.041

0.8689

 Non-CCRT

135 (32.8%)

277 (67.2%)

412

  

37 (27.8%)

96 (72.2%)

133

  

 CCRT

52 (27.1%)

140 (72.9%)

192

  

18 (26.5%)

50 (73.5%)

68

  

BMI

1.061

0.5883

   

0.551

0.7592

 Underweight

8 (24.2%)

25 (75.8%)

33

  

3 (33.3%)

6 (66.7%)

9

  

 Normal weight

100 (32.4%)

209 (57.6%)

309

  

29 (25.4%)

85 (74.6%)

114

  

 Overweight

79 (30.2%)

183 (69.8%)

262

  

23 (29.5%)

55 (70.5%)

78

  
  1. ECOG Eastern Cooperative Oncology Group, CCRT concurrent chemo-radiation therapy, BMI body mass index.
Back to article page